$2.15 Earnings Per Share Expected for CVS Health Co. (NYSE:CVS) This Quarter

Equities research analysts forecast that CVS Health Co. (NYSE:CVSGet Rating) will report $2.15 earnings per share for the current fiscal quarter, Zacks Investment Research reports. Six analysts have issued estimates for CVS Health’s earnings, with the lowest EPS estimate coming in at $2.12 and the highest estimate coming in at $2.20. CVS Health reported earnings per share of $2.42 in the same quarter last year, which suggests a negative year over year growth rate of 11.2%. The company is scheduled to report its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that CVS Health will report full year earnings of $8.33 per share for the current year, with EPS estimates ranging from $8.26 to $8.37. For the next year, analysts anticipate that the business will post earnings of $9.08 per share, with EPS estimates ranging from $8.57 to $10.44. Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that that provide coverage for CVS Health.

CVS Health (NYSE:CVSGet Rating) last posted its quarterly earnings data on Wednesday, May 4th. The pharmacy operator reported $2.22 earnings per share for the quarter, beating the consensus estimate of $2.14 by $0.08. The firm had revenue of $76.83 billion during the quarter, compared to analysts’ expectations of $75.30 billion. CVS Health had a net margin of 2.67% and a return on equity of 15.33%. The company’s quarterly revenue was up 11.2% compared to the same quarter last year. During the same quarter last year, the company posted $2.04 EPS.

Several research analysts have recently issued reports on CVS shares. Sanford C. Bernstein lowered shares of CVS Health from an “outperform” rating to a “market perform” rating and reduced their target price for the company from $122.00 to $112.00 in a research note on Thursday. BMO Capital Markets lifted their price objective on shares of CVS Health from $108.00 to $120.00 in a research note on Thursday, February 10th. StockNews.com initiated coverage on shares of CVS Health in a research note on Thursday, March 31st. They set a “strong-buy” rating on the stock. Raymond James lowered shares of CVS Health from a “strong-buy” rating to an “outperform” rating and lifted their price objective for the stock from $115.00 to $120.00 in a research note on Friday, February 11th. Finally, Tigress Financial lifted their price objective on shares of CVS Health from $122.00 to $125.00 in a research note on Thursday, April 7th. Four equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $115.84.

In other news, EVP Prem S. Shah sold 4,624 shares of the business’s stock in a transaction dated Thursday, March 17th. The shares were sold at an average price of $106.65, for a total value of $493,149.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Prem S. Shah sold 5,346 shares of the business’s stock in a transaction dated Wednesday, March 30th. The shares were sold at an average price of $104.70, for a total transaction of $559,726.20. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 82,283 shares of company stock valued at $8,376,142. Company insiders own 0.69% of the company’s stock.

Several institutional investors have recently made changes to their positions in the company. Macroview Investment Management LLC lifted its position in CVS Health by 128.3% during the first quarter. Macroview Investment Management LLC now owns 242 shares of the pharmacy operator’s stock worth $25,000 after purchasing an additional 136 shares during the period. West Bancorporation Inc. bought a new stake in CVS Health during the fourth quarter worth about $25,000. Claremont Financial Group Inc. bought a new stake in CVS Health during the fourth quarter worth about $26,000. Bell Investment Advisors Inc bought a new stake in CVS Health during the third quarter worth about $26,000. Finally, Stuart Chaussee & Associates Inc. lifted its position in CVS Health by 123.0% during the first quarter. Stuart Chaussee & Associates Inc. now owns 310 shares of the pharmacy operator’s stock worth $31,000 after purchasing an additional 171 shares during the period. 78.00% of the stock is owned by institutional investors.

Shares of NYSE CVS opened at $98.05 on Wednesday. The firm has a market capitalization of $128.57 billion, a PE ratio of 16.29, a price-to-earnings-growth ratio of 1.47 and a beta of 0.78. The company has a current ratio of 0.88, a quick ratio of 0.62 and a debt-to-equity ratio of 0.70. CVS Health has a 1 year low of $79.33 and a 1 year high of $111.25. The firm’s 50-day moving average is $101.16 and its 200-day moving average is $101.32.

The company also recently announced a quarterly dividend, which was paid on Monday, May 2nd. Investors of record on Friday, April 22nd were issued a dividend of $0.55 per share. The ex-dividend date was Thursday, April 21st. This represents a $2.20 dividend on an annualized basis and a yield of 2.24%. CVS Health’s payout ratio is 36.54%.

CVS Health Company Profile (Get Rating)

CVS Health Corporation provides health services in the United States. The company's Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates.

Read More

Get a free copy of the Zacks research report on CVS Health (CVS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.